卵巢癌术后多西他赛静脉加卡铂腹腔灌注和静脉二阶段联合化疗研究

Docetaxel Plus Carboplatin 2 Stage Administration with Itraperitoneal or Intravenous in Patients with Ovarian Cancer Postoperation

[目的]探讨卵巢癌术后多西他赛静脉加卡铂腹腔灌注、静脉二阶段联合化疗的疗效和安全性。[方法]52例卵巢癌术后患者多西他赛75mg/m2静脉滴注d1,卡铂按AUC=5计算d1,前3个周期予腹腔内灌注,后3个周期予静脉滴注,d2、d3水化2d,21d为1个周期。连用2个周期后进行CA125影像学检查,评价疗效和观察不良反应。[结果]平均3.8个周期CA125下降至正常,腹水有效率(RR)为86.2%,实体瘤RR为88.5%。常见不良反应为骨髓抑制、恶心呕吐、脱发、腹泻、口腔黏膜炎和肌肉关节痛等。[结论]卵巢癌术后患者采用多西他赛静脉加卡铂腹腔灌注、静脉二阶段联合化疗疗效肯定,且不良反应可以耐受。

[Purpose] To investigate the efficacy and safety of combination of intravenous docetaxel and carboplatin two-stage treatment with intraperitoneal or intravenous administration in patients with ovarian cancer postoperation. [ Methods ] A total of 52 postoperative ovarian cancer patients received chemother- apy. A treatment of 21 days was defined as a cycle. Docetaxel was administered at a dose of 75 mg/m2 iv. on day 1 and carboplatin according to AUC=5, ip. on day 1 in the first 3 cycles and iv. in the next 3 cycles .Hydration were performed on day 2 and 3 for 2 days in each cycle. CA125 testing and imaging inspection were performed after continuously treatments for 2 cycles to evaluate the efficacy and toxici- ties. [Results] The value of CA125 dropped to normal level after an average of 3.8 cycles＇ treatment. The short-term response rate （RR） for ascites was 86.2% and that for solid tumors was 88.5%. The com- mon toxicities were bone marrow suppression ,nausea, vomiting, alopecia, diarrhea, oral mucositis, muscle and joint pain. [Conclusion] The two-stage postoperative chemotherapy with combination of docetaxel and carboplatin is effective and tolerable in patients with ovarian cancer.